Bridgeway Capital Management’s Boundless Bio BOLD Stock Holding History

Bridgeway Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Buy	128,000 +77,500	+153%	+$119K	0.01%	966
2026 Q1	$55.5K	Hold	50,500	–	–	﹤0.01%	1182
2025 Q4	$60.6K	Hold	50,500	–	–	﹤0.01%	1171
2025 Q3	$62.1K	Hold	50,500	–	–	﹤0.01%	1152
2025 Q2	$51K	Buy	+50,500	New	+$67.1K	﹤0.01%	1136
2025 Q1	–	Sell	-50,000	Closed	-$145K	–	1261
2024 Q4	$145K	Hold	50,000	–	–	﹤0.01%	1058
2024 Q3	$174K	Buy	+50,000	New	+$181K	﹤0.01%	1095

Other funds holding BOLD

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Bridgeway Capital Management's BOLD Position: Q2 2026 in Review

Bridgeway Capital Management increased its Boundless Bio (BOLD) stake by 153% in Q2 2026, buying an estimated $119K and bringing the position to 128,000 shares worth $320K. The position accounts for 0.01% of the portfolio, ranked #966.

Bridgeway Capital Management first reported a position in BOLD in Q3 2024 and has held it in 7 quarters since. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

Bridgeway Capital Management held 128,000 shares of Boundless Bio worth $320K as of Q2 2026.
Bridgeway Capital Management bought 77,500 Boundless Bio shares in Q2 2026, an estimated $119K.
Boundless Bio made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #966 holding.
Bridgeway Capital Management first reported a position in Boundless Bio in Q3 2024 and has held it in 7 quarters since.
40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.